Caribou Biosciences, Inc
2929 7th Street
52 articles with Caribou Biosciences, Inc
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson's disease and other neurodegenerative conditions.
Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has expanded its scientific advisory board (SAB) with the appointment of two new members: Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center; and Christopher Sturgeon, Ph.D.,
Caribou Biosciences Announces Appointment of Industry Leader Andrew Guggenhime to its Board of Directors
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Andrew Guggenhime to its board of directors. Mr. Guggenhime is an accomplished biopharmaceutical industry leader with more than 20 years of experience.
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.
3/10/2021Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week.
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a company overview at upcoming investor conferences in March. Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 1:15 p.m. ET
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
Caribou co-founder and CRISPR pioneer Jennifer Doudna said the company has leveraged its gene-editing technology platform to create a “promising clinical-stage therapeutic and a pipeline of pre-clinical allogeneic CAR-T and CAR-NK cell therapies that are potentially transformative for patients wi...
2/12/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.
AbbVie committed up to another $300 in potential milestone payments.
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the appointment of Jason O’Byrne
Caribou Biosciences Announces Licensing Agreement for scFvs Targeting CD371 to Enable Development of Allogeneic Cell Therapies
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the execution of an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) under which Caribou has rights to fully human anti-CD371 scFvs and intellectual property related thereto in the field of allogeneic CD371-targeted cell therapies including CAR-T, CAR-NK, or iPSC-derived cell products.
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. In awarding the prize to Dr. Doudna, the Swedish Academy cited her contributions to science for the co-development of CRISPR-Cas9, a genome editing breakthrough which has revolutionized biomedicine. The prize was also a
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Dru
Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will serve as Caribou’s clinical leader and oversee the advancement of the Company’s first allogeneic CAR-T cell therapy candidate, expected to start clinical trials later this year. “The experience and e
- Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
Feb. 19, 2020 13:00 UTC BERKELEY, Calif. & RICHMOND, Calif.--( BUSINESS WIRE )-- Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic eng
Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells
Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering with Type I CRISPR-Cas systems.